The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.
Australian researchers said that in a preliminary study they saw sensitivity improvements by adding IL-6 to other clinical measurements.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
The PAVmed subsidiary will have the option to license the biomarkers for a year after the completion of a Phase II study evaluating their accuracy.
The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.
The genotyping test is designed to identify cancer patients with a metabolic disorder that can result in toxicity to a common cancer therapeutic.
